In the article that accompanies this editorial, Rahman et al 2 describe the results from the first three experimental arms of the INSIGhT trial which, to our knowledge, is the first adaptive platform ...

The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless ...

Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the ...

When the I-SPY 2 trial launched in 2010, oncologists heralded it as the future of cancer research. Five pharmaceutical companies put aside their differences to participate in the landmark phase 2 ...

Pharmaceutical companies will accelerate adoption of adaptive clinical trial designs, according to the Tufts Center for Drug Development, to reduce clinical development timelines and costs while ...

Boston – An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments ...

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for ...

LARKSPUR, Calif.--(BUSINESS WIRE)--Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global ...

AUSTIN, Texas--(BUSINESS WIRE)--Berry Consultants, LLC announced today that it is discontinuing its involvement in the I-SPY trials in neoadjuvant breast cancer. Beginning in 2009, Donald Berry, PhD, ...